Canada: Quebec Court Refuses To Authorize Class Action Prompted By Voluntary Withdrawal Of A Drug

For the first time, a Quebec court has refused to authorize a class action proposed after a drug manufacturer announced a voluntary withdrawal. The proposed class action concerned sibutramine, a weight-loss drug for obese patients. From 2000 to 2010, sibutramine was manufactured by Abbott Laboratories and marketed in Canada as the patent medicine Meridia®. Apotex also marketed a generic version, Apo-Sibutramine, in 2010. Both companies voluntarily withdrew the drug in October 2010 at Health Canada's recommendation, after a study linked sibutramine with increased risk of heart attack and stroke in patients with a history of cardiovascular problems. The proposed class action was commenced four days later. The Quebec Superior Court held that the plaintiff had no cause of action against Apotex, and had alleged insufficient facts to warrant authorizing the class action against Abbott.


Sibutramine is an appetite suppressant, formerly prescribed to obese patients as a weight-loss aid. In 2010, the Sibutramine Cardiovascular Outcome Trial (SCOUT), a long-term, large-scale clinical study, found an increased risk of non-fatal heart attacks and strokes in certain patients taking sibutramine who were already at high risk for cardiovascular disease. This study prompted the European Medicines Agency to suspend the marketing authorization for sibutramine, while American and Canadian health authorities recommended a voluntary withdrawal. Both Abbott Laboratories and Apotex followed Health Canada's recommendation to withdraw the drug.

The representative plaintiff, Brent MacMillan, had been prescribed Meridia® by his family doctor in June 2004. Mr. MacMillan alleged that he had suffered a frightening episode that he believed to be a heart attack in the fall of 2005 and immediately stopped taking Meridia®. When the voluntary recall occurred in October 2010, Mr. MacMillan's doctor called him to advise him that he could contact a lawyer if he wished to commence a class action. Mr. MacMillan brought the application for authorization of a class action four days later. He alleged that Abbott and Apotex misrepresented the efficacy of sibutramine in causing weight loss, failed to warn patients of the risk of cardiovascular problems, and marketed the drug despite a risk to benefit ratio that was too high.

The Decision

Quebec courts apply a four-part test in determining whether to authorise a class action. The representative plaintiff must establish each of the following:

  1. the proposed class members' actions raise identical, similar, or connected issues;
  2. the facts alleged appear to support the conclusions sought (the claim has the "appearance of right");
  3. the composition of the plaintiff group makes it difficult or impractical to proceed otherwise; and
  4. the person seeking authorization can adequately represent all members.

In this case, the proposed action failed all but the first element.

The claim against Apotex failed immediately: Justice Roy applied the rule, now well-established in both Ontario and Quebec, that in a class action against multiple defendants, there must be at least one representative plaintiff with a claim against each defendant. In this case, Mr. MacMillan was the only plaintiff, and he had never taken the Apotex product.

As against Abbott, the judge held that the facts alleged by the plaintiff were either insufficient or contradicted by the plaintiff's own evidence. First, the plaintiff had brought the action against the Canadian company, Abbott Laboratories Ltd.; however, the evidence showed that an American company, Abbott Laboratories, was the manufacturer, and the plaintiff failed to bring evidence linking the two entities.

Second, the judge noted that the plaintiff relied for scientific evidence exclusively on the SCOUT study. However, that study was done primarily in patients who took sibutramine against the manufacturer's indications, namely patients with a history of cardiovascular disease, who were over 65, and/or who took the drug for periods much longer than a year. The drug monograph, approved by Health Canada, cautioned against use in each of these circumstances. The study moreover found an increase in heart attack and stroke risk only in patients with a history of cardiovascular problems, for whom the drug was not recommended.

The judge acknowledged that the SCOUT study had affected health authorities' estimate of the risk to benefit ratio for sibutramine. On one hand, the study showed that long-term weight loss from sibutramine was modest and reversible. On the other hand, taking sibutramine increased the risk of heart attack and stroke for patients who already had a history of cardiovascular problems, which is common among obese persons. The SCOUT study did not show, however, that the drug, rather than the patients' obesity, was the cause of any heart attacks or strokes.

The judge noted that, in similar product liability cases in which Quebec courts authorized class actions, the representative plaintiffs had submitted scientific studies or medical records establishing at least an apparent link between the medication and the alleged harmful side-effect. In this case, there was no evidence that persons taking the drug according to the manufacturer's indications were exposed to any increased risk of heart attack or stroke.

Mr. MacMillan also failed to establish an appearance of right in his own case. He admitted having lost more than 5% of his body mass while taking the drug – more than average loss indicated in the drug monograph. Although he regained that weight after stopping treatment with sibutramine, he did not claim to have made any lifestyle changes, which the monograph indicated were necessary to maintain the weight loss.

As regards his alleged heart attack, the judge was even more critical. The judge noted that Mr. MacMillan had never investigated whether he had really experienced a heart attack in fall of 2005, and had made no efforts to verify his hypothesis that that episode was caused by the drug. Medical records showed that Mr. MacMillan took the drug contrary to several indications in the drug monograph. Finally, there was no evidence supporting his allegations that he was still at risk of future problems after discontinuing the drug.

The judge also found that the proposed class definition – all persons who had purchased and/or taken the drug, and their heirs and relatives – was too broad. First, the class had to be restricted to persons who had had heart attacks or strokes after taking the drug, as other persons taking sibutramine would not have suffered any harm. Second, class actions may only be authorized on behalf of relatives of directly injured class members if there is a representative plaintiff for the relatives, which was not the case here. Finally, the SCOUT study had shown an increase in non-fatal heart attacks and strokes only, but not in overall mortality, so there was no reason to include patients' heirs in the class.

The claim also failed the next element of the authorization test, concerning the composition of the plaintiff group. As the plaintiff failed to show that even a single sibutramine patient (including himself) had suffered a heart attack or stroke, the court could not conclude that there was a group of persons who could form a class at all.

On the last element of the test, the judge held that Mr. MacMillan was not an appropriate representative plaintiff, based on his handling of the claim to date.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.